Kainos

Basic Information

Stock Code
4556
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
May 1975
Listing Year
December 1995
Official Website
http://www.kainos.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Towns, Atect, Eiken Chemical, Institute of Immunology, Mizuho Medy, Ito Yogyo, Lobtex, TVE, Sysmex

Overview

Kainos is a pharmaceutical manufacturer established in 1975, having built a significant position in the domestic market through the development and manufacturing of clinical diagnostic reagents and medical devices.

Current Situation

Kainos recorded sales of approximately 5 billion yen, operating income of about 860 million yen, and net profit of about 640 million yen for the fiscal year ended March 2024, maintaining a solid revenue base. Its flagship biochemical and immunological test reagents hold a high share in the domestic hospital market, and it is widely active in fields such as blood transfusion testing equipment/reagents and genetic reagents. Since 2020, it has developed and marketed novel coronavirus-related test reagents, actively pursuing technological innovation. It has entered into capital and business alliances with major pharmaceutical companies such as Sysmex and Asahi Kasei Pharma, working to strengthen joint development and sales networks. It is also advancing efforts on environmental and social issues, including acquiring ISO certifications and continuing local contribution activities. Moving forward, it aims to enhance competitiveness in the medical testing field by entering the gene therapy sector and introducing automation technologies. In the medium term, it positions product diversification and overseas market development as strategic growth drivers.

Trivia

Interesting Facts

  • Company name means 'newborn/innovative' in Greek
  • Launched the world's first enzymatic serum transaminase assay reagent kit
  • Rapidly launched multiple novel coronavirus test reagents simultaneously
  • Holds high market share in Japan's blood transfusion testing field
  • Early development of anti-AAV antibody assay reagent opens path to gene therapy
  • Superior quality management with ISO9001 and ISO13485 certifications
  • Early entry into immunochromatographic in vitro diagnostics
  • Nationwide deployment of locally rooted multi-location sales offices
  • Developed procalcitonin assay reagent for general-purpose analyzers
  • Introduced proprietary automatic filling machines for multiple hospitals

Hidden Connections

  • Accelerating fusion of test reagents and equipment through capital and business alliance with Sysmex
  • Strength in pharmaceutical domain through technology and capital alliance with Asahi Kasei Pharma
  • Jointly developed anti-AAV antibody assay kit with special appointment professor at Jichi Medical University
  • Commercialized pneumonia pathogen gene detection reagent through joint research with Yamaguchi University and Gifu University
  • Distinctive company logo design derived from New Testament teachings
  • Accumulated blood transfusion testing business expertise through alliance with U.S. Immucor
  • Complies with medical safety standards through international ISO certifications
  • In 2021, made significant contributions to infectious disease countermeasures via novel coronavirus test reagent development

Future Outlook

Growth Drivers

  • Stable expansion of diagnostic reagent demand in Japan
  • Ongoing market needs for novel coronavirus test reagents
  • Acceleration of test reagent development in gene therapy field
  • Promotion of automation and labor-saving equipment普及
  • Joint product development and sales channel expansion with capital alliance partners
  • Strengthening of testing services for aging society
  • Niche market capture in research reagent market
  • ESG-conscious sustainable business operations
  • Gradual overseas market entry and partner collaborations

Strategic Goals

  • Establish top-class domestic position in gene therapy testing market
  • Achieve 80% automation rate in test reagent manufacturing
  • Expand annual sales to 10 billion yen scale
  • Pursue environmental load reduction to cut CO2 emissions by 30%
  • Market share expansion through product lineup diversification
  • Promote global expansion via strengthened Sysmex collaboration

Business Segments

Clinical Diagnostic Reagent Manufacturing and Sales

Overview
Provides various test reagents and related equipment to medical institutions to support accurate diagnosis.
Competitiveness
High-precision testing technology and rapid market responsiveness
Customers
  • University hospitals
  • General hospitals
  • Testing centers
  • Clinics
  • Clinical laboratory technicians
Products
  • Biochemical reagents
  • Immunoassay reagents
  • Blood testing equipment
  • Blood transfusion compatibility test reagents

Genetic Testing and Diagnostic Technology

Overview
Provides cutting-edge in vitro diagnostic products in the genetic testing field for research purposes.
Competitiveness
Patented technologies and joint research partnerships
Customers
  • Research institutions
  • Pharmaceutical companies
  • Gene therapy development companies
  • Municipal health agencies
Products
  • NASBA gene amplification reagents
  • Pneumonia pathogen test kits
  • Novel coronavirus test reagents
  • ELISA kits

Blood Transfusion Testing Business

Overview
Provides high-performance devices and reagents for safe blood transfusion diagnostics.
Competitiveness
Comprehensive provision system for transfusion-specific equipment and reagents
Customers
  • Blood centers
  • Large hospitals
  • Clinical testing contractors
Products
  • Automated blood transfusion testing devices
  • Antibody screening cards
  • Blood transfusion compatibility reagents

Quality Control Materials

Overview
Manufactures and sells various quality control materials essential for test quality assurance.
Competitiveness
High-quality management system compliant with international standards
Customers
  • Testing labs
  • Medical institution testing departments
  • Test reagent manufacturers
Products
  • Control solutions
  • Calibrators

R&D Support

Overview
High-performance reagent lineup supporting research and development in biomedicine.
Competitiveness
Product development capability responsive to researcher needs
Customers
  • Basic medical researchers
  • University labs
  • Biotech companies
Products
  • Research measurement reagents
  • Gene-related reagents

Competitive Advantage

Strengths

  • High-precision diagnostic reagent development technology in the domestic market
  • Comprehensive capabilities through collaboration with diverse medical devices
  • Strong partnerships with Sysmex and Asahi Kasei Pharma
  • Abundant patents and proprietary testing technologies
  • Product portfolio covering diverse testing fields
  • Rapid new product development capabilities
  • Established quality management and certification systems
  • Locally rooted sales network
  • Continuous R&D investment
  • Cost optimization through manufacturing automation

Competitive Advantages

  • One of the few domestic manufacturers of automated devices in blood transfusion testing
  • Proprietary NASBA technology for genetic testing reagents
  • Sales channel expansion through capital and business alliance with Sysmex
  • One-stop provision through broad medical test reagent lineup
  • Experience in rapid commercialization of novel coronavirus test reagents
  • High delivery track record and trust with domestic hospitals
  • Technology innovation driven by close collaboration with research institutions
  • Quality assurance through ISO certification of manufacturing processes
  • Establishment of new gene therapy support system through antibody assay kit development
  • Improved productivity through ongoing automation investments in manufacturing equipment

Threats

  • Intensifying competition with major medical equipment manufacturers
  • Risks from stricter regulations in the diagnostic drug market
  • Accelerating pace of technological innovation in genetic testing
  • Profit pressure from emerging low-price competitors
  • Demand stagnation due to domestic population decline
  • Rise of competitors in emerging markets
  • Sudden business environment changes due to infectious disease outbreaks
  • Risk of imported material cost fluctuations from exchange rate changes
  • High R&D costs associated with new technology development
  • Supply chain instability risks

Innovations

2024: Launch of Procalcitonin Assay Reagent 'LATECLE PCT Reagent'

Overview
Developed and began sales of a reagent capable of measuring sepsis biomarkers in about 10 minutes.
Impact
Contributes to both new market development and shortened diagnosis times.

2024: Additional Sales of Gynecology and Gonadal Hormone Immunoassay Panel

Overview
Launched 6 immunoassay reagents for the HISCL series jointly developed with Sysmex.
Impact
Supports improved testing efficiency in gynecology care.

2022: Capital and Business Alliance Agreement with Sysmex

Overview
Agreed to a capital and business alliance to accelerate growth in the immunoassay field.
Impact
Strengthens sales capabilities and promotes R&D collaboration.

2021: Simultaneous Launch of Three Novel Coronavirus Test Reagents

Overview
Marketed antigen and antibody detection test reagents using immunochromatography.
Impact
Responded to domestic testing demand and achieved sales growth.

2020: Investment in Gene Therapy Research Institute to Enter Gene Therapy Field

Overview
Entered new field triggered by joint development of anti-AAV antibody assay kits.
Impact
Strengthens business foundation in future growth areas.

2020: NASBA Method Gene Amplification Technology Patent License Agreement

Overview
Concluded patent agreement with Organon Teknika B.V. in the Netherlands to expand technology use.
Impact
Improves reliability of testing products through proprietary technology.

Sustainability

  • Thorough quality management through ISO13485 certification
  • Production efficiency improvement via factory automation
  • Health education support activities in collaboration with local communities
  • Material optimization to reduce environmental impact
  • Organizational revitalization through utilization of diverse talent